logo-loader
viewMotif Bio PLC

Motif Bio PLC gets ball rolling for iclaprim NDA

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive's Andrew Scott they've initiated a rolling submission of a new drug application to the US Food & Drug Administration for iclaprim.

The new drug application (NDA) for their flagship next-generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is expected to be completed during the second quarter of 2018.

Quick facts: Motif Bio PLC

Price: 0.2333 GBX

AIM:MTFB
Market: AIM
Market Cap: £1.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

RNS

Holding(s) in Company

3 days, 2 hours ago

Second Price Monitoring Extn

3 days, 22 hours ago

Price Monitoring Extension

3 days, 22 hours ago

Second Price Monitoring Extn

4 days, 2 hours ago

Price Monitoring Extension

4 days, 2 hours ago

Holding(s) in Company

6 days, 2 hours ago

Holding(s) in Company

1 week, 3 days ago

2 min read